CYNK-001

Phase 1Biologic

CCelularity Incorporated

CYNK-001 is one of 46 biologic programs targeting Multiple Myeloma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

COVID-19Active, not recruiting

CoronavirusTerminated

Multiple MyelomaPhase 1

Active, not recruiting

COVID-19Phase 1/Phase 2

Active, not recruiting

CoronavirusPreclinical

Terminated

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Bnt162b2

BioNTech

Preclinical

29 2

Biaxin

AbbVie

Preclinical

2 3

Singulair

AstraZeneca

Preclinical

1 4

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 5

Glucocorticoid

AbbVie

Preclinical

1 6

CYNK-001

CCelularity Incorporated

Phase 1

4 7

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 8

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 9

Selenium

SSWOG Cancer Research Network

Preclinical

1 10

MRNA COVID-19 Vaccine

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recurrent1 trial

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

Withdrawn·CCelularity Incorporated·Phase 1/2·NCT05218408

Natural Killer Cell1 trial

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Terminated·CCelularity Incorporated·Phase 1·NCT04310592·27 enrolled

Multiple Myeloma1 trial

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Unknown status·CCelularity Incorporated·Phase 1·NCT04309084·29 enrolled

Coronavirus1 trial

A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19

Terminated·CCelularity Incorporated·Preclinical·NCT04365101·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CYNK-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CYNK-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CYNK-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celularity Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCelularity Incorporated

CYNK-001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Recurrent1 trial

Natural Killer Cell1 trial

Multiple Myeloma1 trial

Coronavirus1 trial

References

Drug Info

Quick Facts

Related News